US Markets Flat in Pre-Bell Following Biggest Weekly Gain of 2024

MT Newswires Live2024-08-19

US stock futures were treading water in Monday's premarket session following the S&P 500's biggest weekly gain of the year, and as investors look ahead to Friday's speech from Federal Reserve Chairman Jerome Powell at an economic symposium in Jackson Hole, Wyoming on Friday.

The Dow Jones Industrial Average futures were off 0.02%, S&P 500 futures gained 0.08%, and Nasdaq futures were up 0.09%.

Oil prices were moving lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude declining 0.74% and 0.71% respectively.

In equities, shares of Applied DNA Sciences (APDN) soared 102% in Monday's premarket activity, extending its 78% gain from Friday. Tonix Pharmaceuticals' (TNXP) shares surged 38% after reporting a narrower Q2 net loss per share and higher revenue from a year earlier. And shares of SciSparc's (SPRC) rose 19% higher after it said Friday that it signed a patent license agreement with Polyrizon to out-license its SCI-160 program to treat pain.

On the losing side, shares of Liquidia (LQDA) plunged 38% after the US Food and Drug Administration granted tentative approval of Yutrepia to treat pulmonary arterial hypertension and pulmonary hypertension, but said final approval won't be granted until the exclusivity of United Therapeutics' Tyvaso DPI expires. Lytus Technologies' (LYT) shares fell 0.3%, adding to a 0.9% loss on Friday. And shares of B. Riley Financial (RILY) dropped 9% after Chairman and co-Chief Executive Bryant Riley made an unsolicited proposal to take the company private for $7 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment